The symptomatic impact of Abn-CBD and two other GPR55 agonists (CID1792197 and CID2440433) was studied using the catalepsy test, which indicated GPR55 as a probable symptomatic target for PD [71]. The gene discussed is GPR55; the disease is Parkinson disease.